Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin Dose Comparison in Allogeneic Stem Cell Transplant
NCT00709592Phase 2Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Jul 2008
- Primary completion
- Feb 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of antithymocyte globulin in non-Hodgkin lymphoma (NHL), leukemia, multiple myeloma (MM), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), sponsored by Virginia Commonwealth University. Started Jul 2008; status: completed.
02
Drugs
antithymocyte globulin
03
Conditions
non-Hodgkin lymphoma (NHL)leukemiamultiple myeloma (MM)acute myeloid leukemia (AML)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00709592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00709592.